Neisseria meningitidis serogroup B outer membrane vesicle vaccine in adults with occupational risk for meningococcal disease.
Vaccination provides a safe and effective means of reducing the risk of laboratory-acquired infection due to some Neisseria meningitidis serogroups. However, there is currently no serogroup B meningococcal vaccine licensed for use in the US. We used an investigational N. meningitidis serogroup B outer membrane vesicle (B:15:P1.7,16) vaccine produced by the National Institute of Public Health (NIPH) in Norway to immunize 20 researchers with occupational risk for disease. Three doses of vaccine were administered via intramuscular injection at 8-week intervals. The vaccine produced moderate or severe pain with 19 (33%) of the 58 doses administered. Reactions were similar following first, second and third doses. The number and severity of reactions peaked at 24 h postvaccination and then gradually waned. Of 16 vaccinees with results available from all blood draws, 12 (75%) showed a fourfold or greater rise in serum bactericidal activity (SBA) against the vaccine type-strain following two doses of vaccine, and 15 (94%) responded after three doses. Geometric mean titers increased by more than sixfold following two doses of vaccine when compared with prevaccination levels, and by more than 11-fold following a third dose. There was no significant difference between SBA measured using the vaccinee's own complement versus a donor complement source. The NIPH vaccine elicited an excellent bactericidal response against the vaccine type-strain in researchers with an occupational risk for disease. It may be useful for other laboratory personnel who routinely work with meningococcal strains containing similar outer membrane antigens. These findings reconfirm that the NIPH vaccine is immunogenic in adults and support the validity of using properly screened human donor complement in serum bactericidal assays against serogroup B meningococci.
Department of Pediatrics, Children's Hospital and Regional Medical Center, Seattle, WA, USA.
M
M
Fischer
G M
GM
Carlone
J
J
Holst
D
D
Williams
D S
DS
Stephens
B A
BA
Perkins
D000328:Adult; D000907:Antibodies, Bacterial / Q000096:biosynthesis / Q000097:blood; D000942:Antigens, Bacterial / Q000009:adverse effects / Q000276:immunology; D016667:Bacterial Capsules; D001428:Bacterial Vaccines / Q000009:adverse effects / Q000276:immunology*; D006801:Humans; D008585:Meningitis, Meningococcal / Q000276:immunology* / Q000517:prevention & control; D009345:Neisseria meningitidis / Q000276:immunology*; D009784:Occupational Diseases / Q000276:immunology* / Q000517:prevention & control; D011135:Polysaccharides, Bacterial / Q000009:adverse effects / Q000276:immunology*; D015164:Vaccines, Inactivated / Q000009:adverse effects / Q000276:immunology*
D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001428:Bacterial Vaccines; D011135:Polysaccharides, Bacterial; D015164:Vaccines, Inactivated; C039455:capsular polysaccharide, meningococcal group B